What changed
$PM — SHORT 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $10.1B | EPS $1.96 vs $1.83 🟢 | Margin 38.4%
💡 Consensus expects 5-6% EPS growth from next-gen products, but IQOS growth is slowing and regulatory risks (menthol ban, plain packaging) are underappreciated. The market is pricing a stable growth story that doesn't match reality.
📉 Reward/risk: 3.0:1
🏢 Business Quality: 6/10
📊 Valuation: rich – P/E 23x adj vs 5yr avg 20x and peers 18x; EV/EBITDA ~15x vs sector 12x; FCF yield ~4.5% below risk-free rate.
🔮 Catalyst: Q2 2026 earnings report
💰 Entry: $180.18, stop $190, target $150
⚖️ Short: PM's bottom-decile quant rank, rich valuation, and slowing IQOS momentum make it a sell; the Q1 beat is already priced, and the next catalyst likely disappoints.
📊 Our read: SHORT. Full analysis →
https://stockduty.xyz/s/PM0625